Eric Baron
Research Subjects
Eric Baron has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Timothy E. Moore
Statistical Consulting Services, Center for Open Research Resources and Support, University of Connecticut, Storrs, CT 06269, USA
3 shared publications - Abhishek Jaiswal
Hartford Healthcare Heart and Vascular Institute, Hartford Hospital, Hartford, CT
2 shared publications William F. Parker
University of Chicago Medicine, Chicago, IL
2 shared publications- Alexander M. Kaizer
Department of Biostatistics and Informatics, School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, USA
1 shared publication - Brian P. Hobbs
Telperian Inc, Austin, TX
1 shared publication - David S. Hong
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
1 shared publication
Latest Publications
- Open Access
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500507
Master Protocol Design With Hybrid Control for Efficient Early-Phase Trial Consolidation
PURPOSE: Master protocols represent transformations, enabling multiple therapies or diseases under a single protocol. These designs streamline therapeutic development by reducing redundancies. Suited for evolving fields such as oncology and global emergencies such as the COVID-19 pandemic, master protocols have been exemplified by studies such as RECOVERY, Solidarity, and I-SPY 2, which accelerated effective treatment identification (with I-SPY 2 focused on molecular subtypes). Recent oncology examples, such as MORPHEUS, evaluate immunotherapy combinations with shared controls. Despite advantages, their application in early-phase oncology remains underutilized amid growing regulatory emphasis on randomization for robust evidence. METHODS: US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) initiatives, such as Project Optimus and Project FrontRunner, emphasize randomization in early-phase oncology trials. However, these initiatives pose challenges, including larger sample sizes, patient and physician reluctance to randomization, and high failure rates from poor accrual. To address these, this article adapts master protocol designs to consolidate early-phase trials for novel therapeutics sharing a common backbone therapy, integrating hybrid controls from published standard-of-care data to minimize randomization to the control arm. RESULTS: By consolidating trials under a shared standard-of-care control arm, the proposed master protocol design reduces total sample size by as much as 55% when compared with independent trials (with control arm sizes 2.4-2.9 times lower), lowers costs and duration, and enhances enrollment through reduced randomization to controls. Incorporating hybrid controls from prior studies and sharing information among arms with common background standard-of-care further improve efficiency, increasing power (reaching 90% overall) while controlling type I error rates acceptable levels. CONCLUSION: Master protocol designs with hybrid controls and Bayesian information sharing enable the efficient integration of randomization into early-phase oncology trials, enhancing efficiency, cost-effectiveness, and patient-centricity while aligning with FDA OCE initiatives.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500507
Open AccessMaster Protocol Design With Hybrid Control for Efficient Early-Phase Trial Consolidation
PURPOSE: Master protocols represent transformations, enabling multiple therapies or diseases under a single protocol. These designs streamline therapeutic development by reducing redundancies. Suited for evolving fields such as oncology and global emergencies such as the COVID-19 pandemic, master protocols have been exemplified by studies such as RECOVERY, Solidarity, and I-SPY 2, which accelerated effective treatment identification (with I-SPY 2 focused on molecular subtypes). Recent oncology examples, such as MORPHEUS, evaluate immunotherapy combinations with shared controls. Despite advantages, their application in early-phase oncology remains underutilized amid growing regulatory emphasis on randomization for robust evidence. METHODS: US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) initiatives, such as Project Optimus and Project FrontRunner, emphasize randomization in early-phase oncology trials. However, these initiatives pose challenges, including larger sample sizes, patient and physician reluctance to randomization, and high failure rates from poor accrual. To address these, this article adapts master protocol designs to consolidate early-phase trials for novel therapeutics sharing a common backbone therapy, integrating hybrid controls from published standard-of-care data to minimize randomization to the control arm. RESULTS: By consolidating trials under a shared standard-of-care control arm, the proposed master protocol design reduces total sample size by as much as 55% when compared with independent trials (with control arm sizes 2.4-2.9 times lower), lowers costs and duration, and enhances enrollment through reduced randomization to controls. Incorporating hybrid controls from prior studies and sharing information among arms with common background standard-of-care further improve efficiency, increasing power (reaching 90% overall) while controlling type I error rates acceptable levels. CONCLUSION: Master protocol designs with hybrid controls and Bayesian information sharing enable the efficient integration of randomization into early-phase oncology trials, enhancing efficiency, cost-effectiveness, and patient-centricity while aligning with FDA OCE initiatives.
- 26 May 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (9) , 1526
Re: Optimizing the handling of missing data in the UNOS database
- 26 May 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (9) , 1526
Re: Optimizing the handling of missing data in the UNOS database
- 7 November 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (3) , 462-468
A systematic review of reporting and handling of missing data in observational studies using the UNOS database
- 7 November 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (3) , 462-468
A systematic review of reporting and handling of missing data in observational studies using the UNOS database
- 2 October 2023
- Published by Taylor & Francis in The American Statistician
- Vol. 78 (2) , 209-219
Bayesian Detection of Bias in Peremptory Challenges Using Historical Strike Data
- 2 October 2023
- Published by Taylor & Francis in The American Statistician
- Vol. 78 (2) , 209-219
Bayesian Detection of Bias in Peremptory Challenges Using Historical Strike Data